195 related articles for article (PubMed ID: 25703441)
1. Cost-effectiveness of therapies for melanoma.
Johnston KM; McPherson E; Osenenko K; Vergidis J; Levy AR; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):229-42. PubMed ID: 25703441
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review.
Gorry C; McCullagh L; Barry M
Value Health; 2020 Jan; 23(1):52-60. PubMed ID: 31952674
[TBL] [Abstract][Full Text] [Related]
3. Who benefits most from adjuvant interferon treatment for melanoma?
Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
[TBL] [Abstract][Full Text] [Related]
4. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
5. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.
Rubio-Rodríguez D; De Diego Blanco S; Pérez M; Rubio-Terrés C
Pharmacoeconomics; 2017 Sep; 35(9):879-893. PubMed ID: 28551858
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib in the treatment of metastatic or unresectable melanoma.
Khoja L; Hogg D
Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514
[TBL] [Abstract][Full Text] [Related]
8. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
9. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
Messori A; Becagli P; Trippoli S; Tendi E
Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.
Lafuma A; Dreno B; Delaunay M; Emery C; Fagnani F; Hieke K; Bonerandi JJ; Grob JJ;
Eur J Cancer; 2001 Feb; 37(3):369-75. PubMed ID: 11239759
[TBL] [Abstract][Full Text] [Related]
11. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O; Hoeller C
Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
[TBL] [Abstract][Full Text] [Related]
12. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanoma: cost and reimbursement issues.
Creagan ET
Semin Oncol; 1989 Feb; 16(1 Suppl 1):45-50. PubMed ID: 2465576
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma.
Look Hong NJ; Petrella T; Chan K
J Surg Oncol; 2015 Mar; 111(4):423-30. PubMed ID: 25422047
[TBL] [Abstract][Full Text] [Related]
16. Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies.
Cashin RP; Lui P; Machado M; Hemels ME; Corey-Lisle PK; Einarson TR
Value Health; 2008; 11(2):259-71. PubMed ID: 18380638
[TBL] [Abstract][Full Text] [Related]
17. A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.
Lau DK; Andrews MC; Turner N; Azad AA; Davis ID; Cebon JS
Melanoma Res; 2014 Apr; 24(2):144-9. PubMed ID: 24463460
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
Crott R; Ali F; Burdette-Radoux S
Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
[TBL] [Abstract][Full Text] [Related]
19. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
20. Rationale for complete metastasectomy in patients with stage IV metastatic melanoma.
Ollila DW; Gleisner AL; Hsueh EC
J Surg Oncol; 2011 Sep; 104(4):420-4. PubMed ID: 21858837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
